NCT01199393

Completed

Genetic Polymorphisms Predict Chemotherapeutic Outcomes in P...

Peking University Cancer Hospital & Institute Source

Compare

Other study identifiers

Sponsor study identifier

snp

Study Type

observational

Actual enrollment (reported)

153

Locations

1 country

Sites

1

Timeline

Study Start

August 2010

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2014

Actual (reported)

Study Completion

May 2015

Actual (reported)

Brief Summary

The investigators want to research whether genetic polymorphisms of drug-metabolizing enzymes can be used to predict chemotherapeutic outcomes in patients with metastatic breast cancer.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 153 participants
Study completion date: May 2015
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
August 2010
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
August 31, 2010
Actual (reported)
First Posted
September 13, 2010
Actual (reported)
Primary Completion
December 2014
Actual (reported)
Study Completion
May 2015
Actual (reported)

Last Updated: July 29, 2015
Status Verified: July 2015
Last Update Submitted: July 27, 2015

Conditions

Breast Neoplasm Drug Therapy Polymorphism,Single Nucleotide

Keywords

breast neoplasmdrug therapypolymorphismgene

Outcome Measures

Primary Outcomes (1)

Response to chemotherapy
Response to chemotherapy is evaluated by Response Evaluation Criteria in Solid Tumors(RESIST).
6 months

Secondary Outcomes (3)

Time to disease progression
1 year
Overall survival
5 years
Toxicity
6 months

Eligibility Criteria

Age18 Years - 75 Years

Sexfemale

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

female patients with metastatic breast cancer

You may qualify if:

Histologically confirmed metastatic breast cancer

Sponsors & Collaborators

Peking University Cancer Hospital & Institute
Otherlead

Study Sites (1)

Beijing Cancer Hospital

Beijing, 100142, China

Biospecimen

Retention: SAMPLES WITH DNA

about 4ml peripheral vein blood

MeSH Terms

Conditions

Breast Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsBreast DiseasesSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

Ningning Dong, PhD
Peking University Cancer Hospital & Institute
PRINCIPAL INVESTIGATOR
Jun Jia, MD
Peking University Cancer Hospital & Institute
STUDY DIRECTOR

Enrollment

153 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Director

Study Record Dates

First Submitted

August 31, 2010

First Posted

September 13, 2010

Study Start

August 2010

Date type not reported

This date has not been verified as actual or estimated.

NCT01256801

Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion

Completed

NCT01653561

A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer

Phase 2Completed

NCT01026116

A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old

Phase 3Completed

NCT01431053

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

Phase 2Unknown

NCT00324610

Tolerance and Pharmacokinetics With Capecitabine 5 Out of 7 Days Regimen

Phase 1/2Unknown

NCT01176916

Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China

Phase 4Completed

Female

An Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

At least one measurable lesion

Normal cardiac, hepatic, renal and bone marrow functions

Life expectancy ≥3 months

Discontinuity of previous chemotherapy for a minimum of 4 weeks

You may not qualify if:

Central nervous system metastases
Serious or uncontrolled concurrent medical illness
History of other malignancies

Contact the study team to confirm eligibility.

Primary Completion

December 2014

Actual (reported)

Study Completion

May 2015

Actual (reported)

Last Updated

July 29, 2015

Record last verified: 2015-07

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01199393
Data provider: ClinicalTrials.gov
Source updated: 2015-07-29
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:39:22 UTC

Locations

CN(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (3)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations